271
Views
1
CrossRef citations to date
0
Altmetric
Articles

Pityriasis alba: toward an effective treatment

ORCID Icon &
Pages 2285-2289 | Received 05 Jun 2021, Accepted 19 Jul 2021, Published online: 01 Aug 2021
 

Abstract

Background

Pityriasis alba is a common skin condition that may be challenging to treat, especially in patients with darker skin type where the hypopigmentation may be more noticeable and represents a major cosmetic concern.

Objectives

This study aims to evaluate the efficacy of three cost-effective treatments of PA in comparison with placebo.

Patients/Methods

This prospective study was conducted on 80 patients complaining from PA and divided into 4 equal groups according the received topical treatment on the target lesions twice daily for 8 weeks (Calcipotriol 0.005% cream, Tacrolimus 0.03% ointment, topical corticosteroid; Clobetasone butyrate 0.05% cream and Petrolatum as Placebo). Clinical evaluation, Physician Global Assessment, Patient’s satisfaction levels as well as point counting planimetry were done for evaluation of the response.

Results

Significant improvement of scaling and erythema within 3 weeks after initiation of therapy and hypopigmentation by the 8th week, except for those received placebo. Tarolimus 0.03% ointment showed simple superiority over both Calcipotriol 0.005% cream and topical corticosteroid as regards repigmenation, although, the later received the highest level of patient satisfaction.

Conclusion

The three treatments were superior to placebo with relative superiority to Tacrolimus 0.03% due to limited side effects.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.